[CALIFORNIA] Centene/Health Net Executives Answer to Regulators, Consumer Advocates and the Public, from Health Access e-news (1/29/16) – “On Friday, January 22, California Department of Insurance (CDI) heard over six hours of testimony from insurance executives, consumer advocates and the public during an official hearing held at the Capitol examining the proposed Centene-Health Net merger. Still, after ample opportunity to provide specific assurances and commitments to California patients, improving the patient experience and passing savings along to consumers, the companies’ executive provided vague and ambiguous statements.” …. see more
[CONNECTICUT] Here’s Why You Should Be Concerned if Anthem and Cigna Merge – online graphic suitable for Pinterest from the Universal Health Care Action Network of Connecticut (1/29/16)
[MASSACHUSETTS] AG warns maker on hepatitis drug costs (Boston Globe, 1/27/16) – “Massachusetts Attorney General Maura Healey, opening a new front in the push to boost access to life-saving drugs, has warned the country’s biggest biotech company that it faces possible legal action unless it lowers the price of two popular hepatitis C medicines.
“In a letter to Gilead Sciences Inc., made public Wednesday, the attorney general wrote that the high price of the company’s Sovaldi drug, $84,000 for a full 12-week course of treatment, and its Harvoni regimen, at $94,500, “may constitute an unfair trade practice in violation of Massachusetts law” because they are too expensive for many patients.” … see more